Cempra Details Launch Plans For Solithromycin
This article was originally published in The Pink Sheet Daily
Executive Summary
Expecting approval for CABP before the end of 2016, Cempra says solithromycin will offer a significant treatment-resistance edge over the earlier macrolide antibiotic azithromycin.
You may also be interested in...
Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its NDA, but Cempra made clear that it won't initiate the study without an external funding source.
Cempra's Solithromycin On Track To Enter Generic, But Resistant, CABP Market
FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.
Solithromycin Proves Safe, Makes Cempra A Deal Target
The antibiotic showed promising results in a late-stage study of the oral formulation, setting the company up as a potential target for acquirers and partnering opportunities – though for now it is signaling its intent to go it alone.